This week's Houston innovators are bringing new exciting things to town. Courtesy photos

3 Houston innovators to know this week

who's who

New and exciting things are coming to town — from a data-focused conference two two startup development organizations announcing a Houston presence. Here are three Houston innovators making it happen in town.

James Y. Lancaster, Texas branch manager of VIC Technology Venture Development

A new venture development company has expanded into Houston with a Texas Medical Center office. Photo courtesy of James Lancaster

An Arkansas-based technology venture development firm had its eyes on Dallas for a Texas expansion, but James Y. Lancaster had a bigger plan. Lancaster, who was named as VIC Technology Venture Development's Texas branch manager, oversees the company's business in Dallas, Houston, and College Station, where he lives. Locally, he will work out of a TMC Innovation Institute office.

"I am excited to be working to TMC member institutions to provide a new avenue for commercializing their technologies, expanding on our fast start in Texas with an exciting opportunity in the Houston innovation ecosystem," Lancaster says in a release.

VIC specializes in taking university-founded research innovations to the marketplace by partnering with technology and business experts at every stage of the process. Read more.

Suzette Cotto, CEO of Innovate Social Media

Houston's DataCon can help prepare business leaders for the digital revolution in AI and machine learning. Photo courtesy of Suzette Cotto

Suzette Cotto, in a guest column for InnovationMap, warns of a not-so-distant future where artificial intelligence and machine learning are a daily business requirement. As companies ready themselves for this digital commonplace, its the C-suite that needs to do some homework in preparation.

DataCon Houston, which takes place on October 10, is one way for C-level execs to get some information. The annual conference brings important concepts around AI and Automation to business leaders, according to Cotto.

"The target audience is not IT professionals, although there will be some in attendance; it's meant primarily to help the C-suite and non-technical leaders know where to begin and where to find that new vocabulary and translative resources," Cotto writes. "AI will affect every person in every business, and we must be ready for the cultural shifts that will come with the technological shifts." Read more.

Ed Bosarge, founder and CEO of Houston Healthspan Innovation Group

Houston millionaire and serial entrepreneur Ed Bosarge has launched a new biotech accelerator. Courtesy of Houston Healthspan Innovation Group

A serial entrepreneur, Ed Bosarge has launched his latest venture. The Houston Healthspan Innovation Group is a biotech startup accelerator for companies in the regenerative medicine industry.

"From day one, Houston Healthspan will play a significant role in shaping Houston's vibrant life sciences scene with its seasoned leadership and state-of-the-art facilities," Bosarge says in a news release. "Houston Healthspan may be a tipping point for the region's life sciences community."

According to the release, the organization has already worked with two companies that have relocated their office to Houston. Read more.

The new biotech accelerator has already worked with two companies, which have relocated their operations to Houston. Getty Images

Houston millionaire starts biotech accelerator for companies focusing on regenerative medicine

Stem cell-erator

A new Houston-based startup accelerator is planning to advance companies focusing on regenerative medicine and stem cell treatment.

Houston Healthspan Innovation Group was created by founder and CEO Ed Bosarge, a local entrepreneur who's made millions of developing health care and finance technology.

"From day one, Houston Healthspan will play a significant role in shaping Houston's vibrant life sciences scene with its seasoned leadership and state-of-the-art facilities," Bosarge says in a news release. "Houston Healthspan may be a tipping point for the region's life sciences community."

The program will provide its participating startups and joint venture partners with expertise and resources in biology, clinical disease, therapeutic delivery systems, finance, and marketing, per the release.

The accelerator will be housed out of the Houston Healthspan Bio Labs —10,000 square feet of lab space just south of the Texas Medical Center. The labs will provide the scientists and researchers with cutting-edge technologies, large cleanrooms, and cGMP cell culture workstations will be used for cell manufacturing, bioprocessing, and therapeutic protocol development. The lab can even handle small-scale biologics manufacturing.

"Gaining access to lab space is a significant hurdle many start-up life sciences companies must overcome," says Dr. Steven Greco, chief science officer at Houston Healthspan. "Our Bio Labs address this need and offer a compelling and ideal setting for start-ups and joint-venture partners to conduct pre-clinical studies and obtain valuable research services."

Houston Healthspan has already started working with two regenerative medicine companies that have both relocated their operations to Houston. Rejenevie Therapeutics™, which moved from New Jersey, develops therapies for immune system restoration as well as age-related illnesses. Formerly based in Hawaii, Tissue Genesis created the Icellator X®, a technology that focuses on stem cell isolation.

"With two collaborator companies like Rejenevie and Tissue Genesis working out of our Houston Healthspan Bio Labs, we can offer significant resources and expertise for start-up and joint-venture partners to thrive and succeed," says Eric Schaeffer, chief strategy officer, in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.